A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
NCT04991831
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Tremor Associated With Tremor Dominant Parkinson's Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 30 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- InSightec
- Last updated on ClinicalTrials.gov
- March 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Miami Neuroscience Institute Baptist Health · Miami, FL
Illinois · 1
- Rush University · Chicago, IL
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
New York · 1
- Weill Cornell Medicine · New York, NY
North Carolina · 1
- Novant Health Brain & Spine Surgery · Huntsville, NC
Ohio · 2
- Cleveland Clinic Foundation · Cleveland, OH
- Miami Valley Hospital · Fairborn, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.